Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Urothelial Carcinoma
Clinical trial register · United States · industry-sponsored

Urothelial Carcinoma Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 19 New York 11 Texas 9 Florida 9 Colorado 7
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Urothelial Carcinoma trials in the USA

27 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
NCT07217496Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer
ImmunityBio, Inc.
Phase 1
18
California
2026-12
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
Duboce Biopharmaceuticals, Inc.
Phase 1
210
Colorado, Michigan, New Jersey, New York, Tennessee, Texas
2026-07-17
Recruiting
A Study of GEN1106 in Participants With Solid Tumors
NCT07416123Solid Tumors, Urothelial Carcinoma
Genmab
Phase 1
103
Connecticut, New York, South Carolina, Tennessee, Texas
2026-04-14
Recruiting
Pfizer
Phase 1/2
132
Arkansas, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2026-03-11
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC
Phase 1
60
Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Tennessee, Texas
2025-08-27
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
California, Connecticut, Massachusetts, Tennessee, Texas
2025-08-20
Recruiting
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
NCT06774131Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma
UroGen Pharma Ltd.
Phase 3
70
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Iowa, Nebraska
2025-08-06
Active, closed
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06331299Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
UroGen Pharma Ltd.
Phase 3
99
California, District of Columbia, Georgia, Indiana, Minnesota, New Jersey, New York, South Carolina
2024-08-29
Recruiting
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
Nammi Therapeutics Inc
Phase 1
100
California, Colorado, Georgia, New York, Texas, Wisconsin
2024-08-28
Recruiting
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
NCT06332755Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma
LG Chem
Phase 1
76
Virginia
2024-06-05
Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma
DrugT-Bren
SystImmune Inc.
Phase 1
280
Alabama, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2024-02-09
Active, closed
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
CG Oncology, Inc.
Phase 3
367
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-14
Recruiting
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
NCT05874921Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent
UroGen Pharma Ltd.
Observational
450
California, Florida, Illinois, Indiana, Iowa, Maryland, Massachusetts, Michigan
2023-11-17
Active, closed
Pacific Edge Limited
Observational
1,000
California, North Carolina, Texas
2023-11-02
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Arizona, California, Minnesota, Pennsylvania, Texas, Washington
2023-09-22
Active, closed
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma
Tyra Biosciences, Inc
Phase 1/2
310
Massachusetts, New York, North Carolina, Ohio, Tennessee, Washington
2022-11-22
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
48
California, Colorado, Illinois, Indiana, Missouri, New York, Ohio, Pennsylvania
2022-11-16
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
372
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Michigan
2022-05-03
Active, closed
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05243550Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
UroGen Pharma Ltd.
Phase 3
240
Arizona, California, Kansas, Maryland, Missouri, New Jersey, New York, Tennessee
2022-03-01
Recruiting
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT04977453Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma
GI Innovation, Inc.
Phase 1/2
317
New York, North Carolina
2021-08-02
Active, closed
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer
Avacta Life Sciences Ltd
Phase 1
158
New York, Texas, Washington
2021-07-16
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
Klus Pharma Inc.
Phase 1/2
1,410
California, Florida, Michigan, Oklahoma, Oregon, Texas, Virginia
2020-02-28
Recruiting
A Multicenter Cancer Biospecimen Collection Study
NCT04510129Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma
Cofactor Genomics, Inc.
Observational
1,650
California
2020-02-05
Active, closed
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
ImmunityBio, Inc.
Phase 2
40
Alaska, Arkansas, California, Florida, Indiana, Iowa, Kentucky, Massachusetts
2018-12-11
Active, closed
Janssen Research & Development, LLC
Phase 1/2
125
Colorado, Kentucky, Maryland, New Jersey, New York, North Carolina, Ohio, Pennsylvania
2018-04-05
Active, closed
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
Exelixis
Phase 1
914
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2017-09-05
Rows per page Showing 1–27 of 27
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/urothelial-carcinoma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 27 of those studies listing the condition Urothelial Carcinoma.

How many Urothelial Carcinoma trials are recruiting in the US?

14 of the 27 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Urothelial Carcinoma), 27 studies
PhaseStudiesRecruitingShare
Phase 110737%
Phase 1/26322.2%
Phase 35118.5%
Observational3211.1%
Phase 23111.1%

Most active sponsors

Lead sponsors with the most studies (Urothelial Carcinoma)
Lead sponsorStudiesRecruiting
UroGen Pharma Ltd.42
ImmunityBio, Inc.20
Pfizer22
Seagen, a wholly owned subsidiary of Pfizer21
AbbVie10
Avacta Life Sciences Ltd10
CG Oncology, Inc.10
Cofactor Genomics, Inc.11
Deciphera Pharmaceuticals, LLC11
Duboce Biopharmaceuticals, Inc.11

Top states

Top states (Urothelial Carcinoma), by number of studies with a site there
StateStudies
California19
New York11
Florida9
Texas9
Colorado7
Massachusetts7
Tennessee7
Arizona6
Connecticut6
District of Columbia6
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.